Lexaria Bioscience Corp., trading on Nasdaq as LEXX, announced it has reached a significant milestone in building its intellectual property portfolio, with 60 patents now granted across major global markets. The company received six new patents since its last update in October 2025, expanding protection for its drug delivery technologies in key therapeutic areas.
The new patents include the first Australian patent in Family #20 for sublingual nicotine delivery, complementing existing patents in the U.S., Canada, and Japan. In Family #21 for hypertension treatments, Lexaria secured its first European Union patent, entering what it describes as the world's second-largest hypertension market after the U.S. The company emphasized that European patent recognition represents an important strategic achievement.
For epilepsy treatments in Family #24, Lexaria obtained two Australian patents and one European Union patent, bringing its total in this family to six U.S. patents, four Australian patents, and one EU patent. In Family #27 for diabetes treatments, the company received one new U.S. patent, giving it two U.S. patents in this category that it considers particularly important given recent successes in the GLP-1 sector.
Lexaria's patent strategy involves initial research of scientific literature followed by animal and human testing to generate data supporting international patent applications. The company stated that granted patents enable it to safely pursue commercial relationships to exploit its innovations. The company's DehydraTECH technology platform improves how drugs enter the bloodstream through oral delivery, potentially increasing bio-absorption and reducing side effects.
The company also reminded shareholders to vote in its upcoming annual meeting on January 27, 2026. Stockholders holding common stock as of December 1, 2025, are entitled to vote, even if they have since sold their shares. Lexaria is asking stockholders to follow board recommendations to vote for all proposals. Proxy materials are available online at https://www.colonialstock.com/LEXX2026, where shareholders can vote using their control number. The voting deadline is 4:00 PM PT on January 26, 2026.
This expansion of Lexaria's patent portfolio matters because intellectual property protection is crucial for biotechnology companies seeking to commercialize innovations. With 60 patents across major markets, Lexaria strengthens its competitive position in drug delivery technology, potentially attracting partnerships and investment. The patents cover treatments for significant health conditions including hypertension, epilepsy, and diabetes, representing substantial market opportunities. For investors, robust patent protection reduces competitive threats and supports long-term value creation, while the shareholder meeting reminder emphasizes corporate governance transparency. The company's continued patent growth suggests ongoing research and development activity that could lead to future commercial applications.
